Listed by the USPTO as MIDDLETON, DANAYA L
Tech Center 4100 • Art Units: 1618 1643 1646 1674 4100
This examiner grants 50% of resolved cases
MIDDLETON, DANAYA L is assigned to tech center 4100 and art unit 1618. The record includes 99 resolved cases and a 49.5% allowance rate. The interview lift is 48.8%, indicating a substantial positive association with allowance outcomes. The median time to allowance is 1317 days.
The listed companies are The Regents of the University of California, Chugai Seiyaku Kabushiki Kaisha, and Boehringer Ingelheim International GmbH. The listed firms are NIXON & VANDERHYE, PC, HARNESS DICKEY (DETROIT), and ArentFox Schiff, LLP & Memorial Sloan-Kettering. The allowance result indicates a mixed outcome profile, while the interview measure supports investing in well-prepared examiner discussions. The case record is useful but limited, so practitioners should avoid treating the association as conclusive. The median timing favors early planning for prosecution resources and claim strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | Final Rejection | Boehringer Ingelheim International GmbH |
| 17212456 | IL-11 ANTIBODIES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 17638519 | IMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY AND OTHER USES | Final Rejection | The Regents of the University of California |
| 18036620 | BIPHASIC SUBCUTANEOUS DOSING REGIMENS FOR ANTI-VLA-4 ANTIBODIES | Final Rejection | BIOGEN MA INC. |
| 17633255 | METHOD OF TREATING KELOIDS | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18538932 | SEQUENTIAL TRANSARTERIAL CHEMOEMBOLIZATION, STEREOTACTIC BODY RADIOTHERAPY, AND IMMUNOTHERAPY (START-FIT) FOR HEPATOCELLULAR CARCINOMA | Non-Final OA | The University of Hong Kong |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.5% of resolved applications examined by Danaya L Middleton were allowed (99 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +48.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Danaya L Middleton took 1,317 days on average from filing to allowance.
Danaya L Middleton examines applications in Art Unit 1618 in Tech Center 4100.
